ME
23andMe Holding Co. Class A · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website 23andme.com
- Employees(FY) 769
- ISIN US90138Q3065
Performance
+5.41%
1W
-15.18%
1M
-36.67%
3M
-52.98%
6M
-79.2%
YTD
-77.11%
1Y
Profile
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.
Technical Analysis of ME 2024-12-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-09 13:47
Whats Next for 23andMe?(Yahoo Finance)
- 2024-12-02 19:07
US Penny Stocks: 3 Picks With Market Caps Under $200M(Simply Wall St.)
- 2024-11-21 16:23
- 2024-11-20 10:25
- 2024-11-20 07:30
- 2024-11-19 18:30
- 2024-11-12 18:14
- 2024-11-12 13:07
- 2024-11-12 10:57
Q2 2024 23andMe Holding Co. Earnings Call(Yahoo Finance)
- 2024-11-12 10:12
- 2024-11-12 02:47
23andMe is falling apart(Yahoo Finance)
- 2024-11-12 01:14
23andMe cuts 40% of its workforce(Yahoo Finance)
- 2024-11-12 00:29
- 2024-11-12 00:14
- 2024-11-11 23:12
- 2024-11-11 18:30
- 2024-11-11 09:20
- 2024-11-11 05:55
- 2024-11-11 05:20
- 2024-11-11 04:30
- 2024-11-07 04:54
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results(Globenewswire)
- 2024-11-06 18:30
23andMe to Report Q2 FY2025 Financial Results(Globenewswire)
- 2024-10-30 21:55
- 2024-10-30 19:34
- 2024-10-30 05:00
23andMe Regains Compliance With Nasdaq Listing Requirements(Globenewswire)
- 2024-10-29 07:30
23andMe Appoints Three New Independent Directors to Board(GlobeNewswire)
- 2024-10-28 19:30
23andMe Appoints Three New Independent Directors to Board(Globenewswire)
- 2024-10-28 00:27
- 2024-10-24 17:00
- 2024-10-24 03:34
The crisis at 23andMe, explained(Yahoo Finance)
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.